Xenetic Biosciences, Inc. (XBIO)

menu

The American Cancer Society estimates that there will be about 60,050 new cases of uterine cancer diagnosed in 2016 in the US.

Do you know the importance of the number 60,050? Test your knowledge w/ this week's trivia question: https://t.co/cNsKvjXTIL
— Xenetic Biosciences (@XeneticBio) June 29, 2016

Enhancing Lives with Transformative Therapies

Xenetic Biosciences is clinical-stage biopharmaceutical company focused on discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics.

More About Us

Combatting Disease Through Innovative Therapies

Product Pipeline

Transformative Technologies

Our proprietary and patented technologies are being utilized to create life-changing therapies.

Our Novel Technologies

Strong Partnerships Lead to Revolutionary Results

We actively pursue partnerships with biotechnology and pharmaceutical companies to co-develop new product candidates and more.

Latest News

Oct 02, 2017

Xenetic Biosciences Provides Update on Annual Meeting of Stockholders

Aug 23, 2017

Xenetic Biosciences Announces Dismissal of Annual Meeting of Stockholders

Recent Event

Oct 5, 2017

Tweets

Stock Information • View Detailed Stock Information

NASDAQ: XBIO Xenetic Biosciences, Inc.

Price

Change

Volume

Day Range

52 Week Range

Get Email Alerts

Stay informed about our latest new and updates